[WEBINAR] Advances in HIV Detection and ScreeningWednesday, December 20, 2017
In the past three decades, AIDS has transformed from a terminal diagnosis to a manageable, chronic illness. However, of the more than 36 million people living with HIV globally, only half know their status.
But with early detection and treatment, people with HIV can live longer and healthy lives.
Abbott, (formerly Alere), is now offering the only FDA cleared antigen/antibody combination HIV screening test at the point of care, Alere Determine™ HIV-1/2 Ag/Ab Combo to CPG members. The combination antigen/antibody test allows for earlier detection of HIV infections enabling linkage to care sooner.
Join Abbott Marketing Manager, Dotty Peterson MT(ASCP), to learn how this point of care HIV screening test can make an impact on improving patient outcomes in your health center.
What you can expect to learn:
How the antigen/antibody screening test works
The importance of early detection
Abbott’s partnership with CPG